Javascript is not enabled in your web browser

This site uses javascript to enhance your browsing experience. Our vision tests require javascript and will not work properly if javascript is disabled. Please enable javascript in your web browser to access all features of this site.

Welcome to MyVisionTest.com, where patients with macular degeneration and other macular diseases can test their vision online. We offer our services free of charge. To use our test online you must first register here. Read the tutorial to learn more.

This site has been designed to be accessible by the visually impaired. Should you have any difficulties, please contact us.

TEST YOUR VISION NOW

Featured Articles

Select Article:
cardiovascular system

Avastin but not Lucentis increases risk of blood clots

Avastin and Lucentis are very different molecules with similar pharmacologic effects. Avastin have a longer half-life, which means it sticks around in the body longer before being broken down and excreted. The longer half-life may mean that it has a higher propensity to cause unwanted side effects than Lucentis. We have seen signs of this in the...

cardiovascular system

Safety of anti-VEGF therapy for AMD

It would be a mistake to assume that the risks associated with intravitreal Avastin use are the same as those for Lucentis. Chemically, the two molecules are very different. The vigorous studies that have been conducted on Lucentis reveal that there are few significant risks associated with its use. It is tempting to assume that the same is true...

Avastin

Benefits of the treat-and-extend approach for AMD therapy

The argument in favor of using Avastin over Lucentis is almost always economic. Because Avastin is much cheaper than Lucentis, patients and their insurance provider can save lots of money by using Avastin. However, the "treat and extend" dosing strategy reveals another potential benefit of Avastin - its longer half-life. There are several studies...

Laser eye surgery

Selective retina therapy for acute central serous chorioretinopathy

The search continues for a safe and effective means of speeding the resolution of acute CSC. Because most cases of acute CSC will resolve fully without intervention, it is imperative that any treatment that is undertaken have a very low risk of adverse effects. Safety-enhanced photodynamic therapy is currently the most appealing of the available...

Recent News

Eylea
Jan 16, 2012
A phase 3 study of the efficacy of Eylea injections to treat neovascular AMD has shown sustained improvement in visual acuity at 96 weeks, Regeneron Pharmaceuticals and Bayer Healthcare announced in a press release. In the first year of the parallel VIEW 1 and VIEW 2 studies, patients received Eylea (aflibercept, Regeneron Pharmaceuticals)...

Full Article


Eylea
Jan 16, 2012
Genentech and Regeneron Pharmaceuticals have agreed to a partial settlement with regard to ophthalmic sales of aflibercept injections in the United States, according to a press release. Under the plan, Regeneron will receive a non-exclusive license to certain patents for VEGF receptor proteins as well as to other technology patents, the release...

Full Article


Racial groups
Jan 16, 2012
Age-related Macular Degeneration (AMD) has long been thought to be more frequent in non-Hispanic whites than in blacks in the United States. This was based on observations reported in clinical case series. The use of new AMD classification schemes and severity scales in large population-based studies has confirmed that non-Hispanic whites have...

Full Article


News Topics

adverse drug effects AMD Amsler grid animal study Avastin blindness c-reactive protein Canada cardiovascular disease cataract CATT central serous chorioretinopathy children cholesterol clinical trial CNV combo therapy depression diabetes diabetic retinopathy diet dosing strategy drug delivery dry AMD eccentric viewing economics endophthalmitis epidemiology epiretinal membrane European Union FDA fish Foresee PHP genetics geographic atrophy glaucoma inflammation iron Japan low vision Lucentis Macugen macular edema Medicare myopia nanoparticles NHS NICE OCT photodynamic therapy polypoidal choroidal vasculopathy preferred retinal locus prognosis PrONTO racial differences reading skills retinal angiomatous proliferation retinal pigment epithelium retinal vein occlusion risk factors RNA interference seasonal variation steroid sunlight surgery TASS teacher tetracycline tobacco transplantation UK uveitis vascular disrupting agent VEGF VEGF Trap vision test wet AMD women Zybrestat
More topics

About MyVisionTest

MyVisionTest.com has been developed to supplement the traditional Amsler Grid for those patients that have been instructed by their eye doctor to monitor their vision at home. MyVisionTest employs a technique known as entoptic perimetry to detect defects in your vision. Research has found entoptic perimetry to be superior to the traditional Amsler grid in detecting such defects. We also offer you the ability to save and review past test results, making it easier for you to detect changes in your vision over time.

Learn more

MyVisionTest Tutorial

If you are new to MyVisionTest, please take a moment to review our tutorial and try out the demo. The vision test requires that you have free multimedia software (Flash) installed and properly configured on your computer. If you are uncertain whether this software is currently installed on your computer, please take a moment to use our troubleshooter to test your system for compatibility with MyVisionTest.

View the MyVisionTest Tutorial

Test your computer for compatibility with MyVisionTest

MyVisionTest Demonstration Mode

Download Amsler Grid